Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
Catherine Diefenbach, Brad S. Kahl, Andrew McMillan, Javier Briones, Lalita Banerjee, Raúl Córdoba, Fiona Miall, John M. Burke, Jamie Hirata, Yanwen Jiang, Joseph N. Paulson, Yi Meng Chang, Lisa Musick, Pau Abrisqueta
Topics & Concepts
LenalidomideMedicineFollicular lymphomaObinutuzumabInternal medicineRituximabOncologyLymphomaCohortNeutropeniaTolerabilityBrentuximab vedotinGastroenterologyChemotherapyAdverse effectMultiple myelomaCD30Lymphoma Diagnosis and TreatmentOvarian cancer diagnosis and treatmentCutaneous lymphoproliferative disorders research